Type of Meeting: Postal Ballot (remote e-voting only, no physical meeting)
Cut-off Date for Voting Rights: Friday, 21st August 2026
Voting Period: Commences on Friday, 28th August 2026 at 09:00 AM IST and ends on Saturday, 26th September 2026 at 05:00 PM IST
Result Declaration: On or before Tuesday, 29th September 2026
Summary of Proposed Resolutions and Implications
Item No. 1: Amendment in Object Clause of Memorandum of Association
Resolution Type: Special Resolution
Purpose: To expand the company's main objects to include medical technology and healthcare-related activities. The new objects will enable the company to engage in:
Research, innovation, design, development, engineering, manufacturing, assembling, fabrication, processing, testing, validation, installation, commissioning, licensing, and commercialization of medical devices, medical equipment, diagnostic systems, surgical instruments, surgical robotic systems, implantable devices, wearable healthcare devices, AI-based healthcare technologies, healthcare software, digital health platforms, telemedicine systems, and hospital automation solutions.
Acting as manufacturers, buyers, sellers, importers, exporters, distributors, stockists, wholesalers, retailers, agents, representatives, licensors, franchisees, and dealers in all kinds of medical technology products and healthcare devices.
Entering into strategic alliances, collaborations, technical partnerships, joint ventures, licensing arrangements, technology transfer agreements, franchise arrangements, and OEM agreements with Indian and foreign companies, institutions, research organizations, hospitals, universities, and governments.
Establishing, acquiring, developing, constructing, operating, maintaining, leasing, managing, and promoting Medical Technology Parks, healthcare industrial clusters, research laboratories, incubation centers, innovation hubs, manufacturing units, clean-room facilities, testing centers, warehouses, and allied infrastructure.
Providing installation, commissioning, maintenance, repair, calibration, validation, technical support, consulting, training, certification, educational programs, and skill development services relating to medical devices and MedTech products.
Developing, acquiring, licensing, marketing, maintaining, and operating healthcare software, AI systems, machine learning applications, cloud-based healthcare platforms, electronic medical record systems, hospital information systems, remote monitoring systems, and cybersecurity solutions for healthcare.
Implications: This expansion is intended to diversify the company's business activities, broaden its revenue base, and explore new growth avenues in the MedTech sector. The company has identified this sector as promising due to encouraging business interest, market response, and ongoing discussions for strategic tie-ups and collaborations.
Item No. 2: Change of Name and Consequential Amendment in Memorandum and Articles of Association
Resolution Type: Special Resolution
Purpose: To change the company's name from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited' to better reflect its proposed expansion into the medical technology sector. The new name has been confirmed as available by the Ministry of Corporate Affairs vide letter dated 14th August 2026.
Implications: The change of name will align the corporate identity with the proposed business strategy and future growth plans. It will not affect the company's legal status, rights, obligations, liabilities, or continuity. All contracts, agreements, arrangements, licenses, permissions, proceedings, assets, liabilities, rights, and obligations will continue unaffected.
Voting Process and Methods
Voting Method: Remote e-voting only (no physical ballot forms accepted) through NSDL's e-voting platform.
Eligibility: Members whose names appear in the Register of Members/List of Beneficial Owners as on the cut-off date (21st August 2026).
Notification: The Postal Ballot Notice is sent only through electronic mode to members who have registered their email addresses with their Depository Participants or the Registrar and Share Transfer Agent.
CDSL's Easi/Easiest facility for CDSL account holders
Depository Participants' login credentials
NSDL Mobile App 'NSDL Speede'
Helpdesk Details:
NSDL: evoting@nsdl.com or 022-48867000
CDSL: helpdesk.evoting@cdslindia.com or toll-free 1800225533
Key Voting Outcomes
Total Votes Cast: Not available yet (voting period is from 28th August to 26th September 2026)
Percentage in Favor and Against: To be declared after voting concludes
Participation Breakdown by Shareholder Category: To be provided in the scrutinizer's report
Result Declaration: The results will be announced on or before 29th September 2026 and will be displayed on the company's website (www.shukrapharmaceuticals.com), NSDL's website (www.evoting.nsdl.com), and communicated to BSE and NSE.
Scrutinizer's Role and Findings
Appointed Scrutinizer: Mrs. Rupal Patel (FCS-6275, CP No-3803), Practicing Company Secretaries, Ahmedabad
Role: To scrutinize the postal ballot process in a fair and transparent manner.
Findings: The scrutinizer will submit a report to the Chairman or authorized person after the completion of the e-voting process. The report will detail the voting results and confirm the validity of the process.
Compliance with Laws and Regulations
The postal ballot is conducted in compliance with:
Sections 108, 110, and 102 of the Companies Act, 2013
Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014
MCA Circulars dated April 08, 2020; April 13, 2020; May 20, 2020; June 15, 2020; September 28, 2020; December 31, 2020; June 23, 2021; December 08, 2021; May 05, 2022; December 28, 2022; September 25, 2023; and September 22, 2025
Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India
For the name change, the company has obtained an auditor's certificate under SEBI Regulation 45 from Shah Sanghvi & Associates, Chartered Accountants (Firm Registration No.: 140107W). The certificate confirms compliance with:
Regulation 45(1)(a): No name change in the preceding one year (compliant)
Regulation 45(1)(b): At least 50% of total revenue from new activity suggested by new name (not compliant, as no revenue has been generated from MedTech activities yet)
Regulation 45(1)(c): At least 50% investment in new activity relative to total assets (compliant, as investment exceeds 50% of total assets)
Names and Roles of Signatories
Issued By: Shivkant Dhakad, Company Secretary (Membership No. A80894)
Authorized Signatory: Dakshesh Shah, Chairman & Managing Director (DIN: 00561666)
Scrutinizer: Mrs. Rupal Patel, Practicing Company Secretary (FCS-6275, CP No-3803)
Auditor: Ravi Shah, Partner of Shah Sanghvi & Associates, Chartered Accountants (Membership No: 149091)
Registrar and Share Transfer Agent: Purva Sharegistry (India) Private Limited
Shareholder Services: Support for email registration and voting assistance is available at support@purvashare.com or by phone at 22-2301 2518 / 6761.
Document Availability: The Postal Ballot Notice and supporting documents are available on the company's website, BSE website (www.bseindia.com), NSE website (www.nseindia.com), and NSDL's e-voting website (www.evoting.nsdl.com).
Inspection of Documents: All material documents referred to in the explanatory statement are available for inspection at the registered office during working hours until the last date of voting. Members can also request electronic copies by emailing info@shukrapharmaceuticals.com from their registered email address.
